Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
Apotex Inc.
Indication:
Metastatic Colorectal Cancer (mCRC) Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer Malignant Glioma (WHO Grade IV) - Glioblastoma
Last updated:
August 18, 2021
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Metastatic Castration-Sensitive Prostate Cancer
Last updated:
August 17, 2021
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated:
August 16, 2021
Status:
Concluded with an LOI
Manufacturer:
Takeda Canada Inc.
Indication:
Crohn's disease
Last updated:
August 13, 2021
Status:
Concluded with an LOI
Manufacturer:
Takeda Canada Inc.
Indication:
Ulcerative Colitis
Last updated:
August 13, 2021
Blood glucose test strips (blood glucose test strips)
Status:
Concluded with an LOI
Manufacturer:
Tykess Pharmaceuticals Inc.
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated:
August 12, 2021
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), for first-line treatment of adult patients
Last updated:
August 11, 2021
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), for first-line treatment of adult patients
Last updated:
August 11, 2021
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Ovarian Cancer: Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy
Last updated:
August 11, 2021
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Ovarian Cancer, monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
Last updated:
August 11, 2021